$CTMX
CytomX Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023060201 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $26.61M $26.38M
YoY Change 2712.58% 55.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.827M $6.810M
YoY Change -22.25% -35.08%
% of Gross Profit
Research & Development $19.39M $16.45M
YoY Change -0.91% -45.84%
% of Gross Profit
Depreciation & Amortization $486.0K $500.0K
YoY Change -20.07% -19.74%
% of Gross Profit
Operating Expenses $27.21M $23.26M
YoY Change -8.16% -43.07%
Operating Profit $3.123M
YoY Change -113.04%
Interest Expense $2.503M $2.700M
YoY Change 241.94% 338.31%
% of Operating Profit 86.46%
Other Income/Expense, Net $9.000K -$7.000K
YoY Change 800.0% -123.33%
Pretax Income $1.906M $5.815M
YoY Change -106.82% -124.96%
Income Tax $1.069M $2.823M
% Of Pretax Income 56.09% 48.55%
Net Earnings $837.0K $2.992M
YoY Change -102.99% -112.84%
Net Earnings / Revenue 3.15% 11.34%
Basic Earnings Per Share
Diluted Earnings Per Share $0.01 $0.04
COMMON SHARES
Basic Shares Outstanding 66.99M 66.77M
Diluted Shares Outstanding 80.99M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $174.5M $194.1M
YoY Change -9.88% -0.09%
Cash & Equivalents $17.17M $26.02M
Short-Term Investments $157.3M $168.1M
Other Short-Term Assets $4.995M $4.700M
YoY Change -33.1% 9.86%
Inventory
Prepaid Expenses
Receivables $3.432M $2.419M
Other Receivables $0.00 $0.00
Total Short-Term Assets $182.9M $201.2M
YoY Change -22.85% 0.46%
LONG-TERM ASSETS
Property, Plant & Equipment $16.18M $4.060M
YoY Change 218.97% -28.9%
Goodwill $949.0K $949.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000M $87.00K
YoY Change 3603.7% -90.28%
Total Long-Term Assets $18.86M $19.96M
YoY Change -20.74% -23.84%
TOTAL ASSETS
Total Short-Term Assets $182.9M $201.2M
Total Long-Term Assets $18.86M $19.96M
Total Assets $201.8M $221.2M
YoY Change -22.65% -2.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.458M $1.705M
YoY Change -48.1% -67.06%
Accrued Expenses $22.19M $20.69M
YoY Change -22.23% -33.99%
Deferred Revenue $132.3M $124.4M
YoY Change 9.07% 102.85%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $155.9M $146.8M
YoY Change 2.17% 50.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $93.33M $2.757M
YoY Change -51.9% -97.25%
Total Long-Term Liabilities $93.33M $2.757M
YoY Change -51.9% -97.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $155.9M $146.8M
Total Long-Term Liabilities $93.33M $2.757M
Total Liabilities $249.2M $272.4M
YoY Change -28.1% 37.57%
SHAREHOLDERS EQUITY
Retained Earnings -$723.4M -$724.3M
YoY Change 0.08% 19.7%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$47.45M -$51.24M
YoY Change
Total Liabilities & Shareholders Equity $201.8M $221.2M
YoY Change -22.65% -2.35%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $837.0K $2.992M
YoY Change -102.99% -112.84%
Depreciation, Depletion And Amortization $486.0K $500.0K
YoY Change -20.07% -19.74%
Cash From Operating Activities -$21.96M -$18.30M
YoY Change 1475.54% -45.93%
INVESTING ACTIVITIES
Capital Expenditures $266.0K $0.00
YoY Change 46.15% -100.0%
Acquisitions
YoY Change
Other Investing Activities $13.13M -$43.00M
YoY Change -86.87%
Cash From Investing Activities $12.87M -$42.90M
YoY Change -87.11% 10363.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 244.0K 29.70M
YoY Change 28.42%
NET CHANGE
Cash From Operating Activities -21.96M -18.30M
Cash From Investing Activities 12.87M -42.90M
Cash From Financing Activities 244.0K 29.70M
Net Change In Cash -8.853M -31.50M
YoY Change -108.98% -8.04%
FREE CASH FLOW
Cash From Operating Activities -$21.96M -$18.30M
Capital Expenditures $266.0K $0.00
Free Cash Flow -$22.23M -$18.30M
YoY Change 1310.47% -45.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
515-3185
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Trading Symbol
TradingSymbol
CTMX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66988904
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26024000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193650000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
168086000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2419000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35986000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4675000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7466000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
201204000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
237102000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4060000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5072000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
766000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
875000
CY2023Q3 us-gaap Goodwill
Goodwill
949000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10490000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22191000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32782000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
23261000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
40857000
us-gaap Operating Expenses
OperatingExpenses
80485000
us-gaap Operating Expenses
OperatingExpenses
124867000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3123000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29710000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5878000
CY2022Q4 us-gaap Goodwill
Goodwill
949000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13184000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15949000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2023Q3 us-gaap Assets
Assets
221167000
CY2022Q4 us-gaap Assets
Assets
260891000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1705000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2809000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20689000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28532000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
124396000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
121267000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
146790000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
152608000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
112261000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
180059000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10597000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13975000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2757000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q3 us-gaap Liabilities
Liabilities
272405000
CY2022Q4 us-gaap Liabilities
Liabilities
346642000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
673109000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
637117000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-63000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-724285000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-722879000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-51238000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-85751000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221167000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260891000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26384000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11147000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
74607000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33040000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16448000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30367000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58294000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92085000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6813000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91827000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2699000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
616000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7334000
us-gaap Investment Income Interest
InvestmentIncomeInterest
946000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
339000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5815000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29064000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1417000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90542000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2823000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2823000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2992000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29064000
us-gaap Net Income Loss
NetIncomeLoss
-1406000
us-gaap Net Income Loss
NetIncomeLoss
-90542000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
367000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-73000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-553000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2894000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28697000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1479000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91095000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.04
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.44
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.38
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.04
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.44
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.38
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80731951
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65912334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71225433
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65618162
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80991722
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65912334
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71225433
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65618162
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-85751000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
16000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3311000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-86637000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
291000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2371000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
9000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1087000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-85027000
CY2023Q3 ctmx Issuance Pre Funded Warrants Net Of Issuance Cost
IssuancePreFundedWarrantsNetOfIssuanceCost
29669000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1226000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-98000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2992000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-51238000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-459000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3370000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-677000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31981000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-29740000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
360000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4490000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-243000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29496000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-54538000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2695000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
367000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29064000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-80540000
us-gaap Profit Loss
ProfitLoss
-1406000
us-gaap Profit Loss
ProfitLoss
-90542000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1580000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1725000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5193000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
47000
us-gaap Share Based Compensation
ShareBasedCompensation
6006000
us-gaap Share Based Compensation
ShareBasedCompensation
10555000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2765000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-2532000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33567000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
986000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2792000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
60000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1098000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2441000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-8465000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5897000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-64669000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-29299000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34072000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109395000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1558000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
312966000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
150000000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-163540000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1558000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
29669000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
317000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
458000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29986000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
458000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-167626000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-110495000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194567000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26941000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95952000
us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_to_condensed_financial_statements" style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Descriptio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n of the Business</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company developing potent biologics designed to be preferentially localized to tumors. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26024000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193650000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95035000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205530000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26941000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194567000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95952000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206447000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.38
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2992000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29064000
us-gaap Net Income Loss
NetIncomeLoss
-1406000
us-gaap Net Income Loss
NetIncomeLoss
-90542000
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
66779192
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
65912334
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
66523404
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
65618162
CY2023Q3 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
13952759
CY2022Q3 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
4702029
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80731951
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65912334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71225433
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65618162
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80731951
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65912334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71225433
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65618162
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
259771
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80991722
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65912334
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71225433
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65618162
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.04
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.44
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.04
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.44
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.38
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25910111
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16438937
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19426965
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15560598
CY2023Q3 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
195429000
CY2023Q3 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
63000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
195366000
CY2022Q4 ctmx Cash Cash Equivalents And Investments Amortized Cost Basis
CashCashEquivalentsAndInvestmentsAmortizedCostBasis
95564000
CY2022Q4 ctmx Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
95574000
CY2023Q3 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
7970000
CY2022Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
13089000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7097000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8060000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
821000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1413000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4458000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4082000
CY2023Q3 ctmx Restructuring Expenses
RestructuringExpenses
0
CY2022Q4 ctmx Restructuring Expenses
RestructuringExpenses
1627000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
343000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
261000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20689000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28532000
CY2023Q3 us-gaap Revenues
Revenues
26384000
CY2022Q3 us-gaap Revenues
Revenues
11147000
us-gaap Revenues
Revenues
74607000
us-gaap Revenues
Revenues
33040000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
301326000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3921000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
68590000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
236657000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
284760000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3401000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
32701000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
255460000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
236700000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13289838
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1779373
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.29
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16535
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1761008
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.23
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13291668
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.15
us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
2800000
CY2023Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2800000
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
400000
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5700000
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2022Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
7970000
CY2022 us-gaap Payments For Restructuring
PaymentsForRestructuring
5812000
CY2022 ctmx Change Of Estimates
ChangeOfEstimates
-307000
CY2022 us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-175000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1676000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1507000
ctmx Change Of Estimates
ChangeOfEstimates
-169000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q3 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Remainder Of Fiscal Year
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsRemainderOfFiscalYear
325000
CY2023Q3 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Next Twelve Months
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInNextTwelveMonths
1333000
CY2023Q3 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Year Two
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInYearTwo
1379000
CY2023Q3 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Due In Year Three
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueInYearThree
1067000
CY2023Q3 ctmx Lessee Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
LesseeOperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
4104000

Files In Submission

Name View Source Status
ctmx-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctmx-20230930_cal.xml Edgar Link unprocessable
0000950170-23-060201-index-headers.html Edgar Link pending
0000950170-23-060201-index.html Edgar Link pending
0000950170-23-060201.txt Edgar Link pending
0000950170-23-060201-xbrl.zip Edgar Link pending
ctmx-20230930.htm Edgar Link pending
ctmx-20230930.xsd Edgar Link pending
ctmx-ex10_1.htm Edgar Link pending
ctmx-ex31_1.htm Edgar Link pending
ctmx-ex31_2.htm Edgar Link pending
ctmx-ex32_1.htm Edgar Link pending
ctmx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
ctmx-20230930_def.xml Edgar Link unprocessable
ctmx-20230930_lab.xml Edgar Link unprocessable
ctmx-20230930_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending